Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology · Autoimmune Polyendocrine Syndrome Type 3

Building Your Care Team: Standard of Care & Management Strategy

At a Glance

Autoimmune Polyendocrine Syndrome Type 3 (APS-3) requires a highly coordinated, multidisciplinary care team led by an endocrinologist. Because the endocrine system is interconnected, treating one condition like thyroid disease directly impacts others like diabetes, requiring dynamic monitoring.

Managing Autoimmune Polyendocrine Syndrome Type 3 (APS-3) is not just about treating individual diseases; it is about managing the “conversations” between them. Because your organs and hormones are all part of one interconnected system, a change in one condition often forces a change in the others.

The Power of the “Anchor” Treatment

The most common medication in APS-3 is levothyroxine (synthetic thyroid hormone) [1]. While this medication is straightforward, it acts as a “metabolic dial” for your entire body.

  • Levothyroxine & Insulin (Subtype 3A): Thyroid hormone levels directly impact how your body processes insulin [2]. If your thyroid is underactive (hypothyroidism), insulin stays in your system longer, which can cause unexpected low blood sugars. When you start levothyroxine, your metabolism normalizes, meaning your body clears insulin faster. This typically requires you to increase your insulin doses to avoid high blood sugars [3][2].
  • Levothyroxine & B12 (Subtype 3B): While the thyroid medication itself doesn’t stop B12 from being absorbed, the reason you have thyroid disease (autoimmunity) is often the same reason you might have autoimmune gastritis [4]. This makes monitoring your iron and B12 levels just as important as monitoring your thyroid [5].

Your Multidisciplinary Care Team

Because APS-3 crosses different organ systems, you cannot rely on just one type of doctor. A “Gold Standard” care team usually includes:

  1. Endocrinologist (The Captain): Manages thyroid, diabetes, and other hormone-producing glands. They should be the primary coordinator of your care [6].
  2. Gastroenterologist: Essential if you have Subtype 3B or Celiac disease. They manage B12 replacement and perform the necessary screenings of your stomach and gut [7].
  3. Rheumatologist: Involved if you have Subtype 3D to manage systemic inflammation in joints or tissues [8].
  4. Primary Care Physician (PCP): The “glue” who monitors your general health and ensures you are up to date on screenings.

Critical Safety: Monitoring and Pitfalls

The biggest risk in APS-3 is “Siloed Care”—when one doctor treats your thyroid without knowing what your diabetes doctor is doing.

  • The 3-to-5 Year Rule: For those with APS-3B (pernicious anemia/gastritis), consensus guidelines now recommend an endoscopy (a camera used to look inside the stomach) every 3 to 5 years [7]. This is because autoimmune gastritis can cause precancerous changes that must be caught early [9].
  • Dynamic Monitoring: Your care should be “dynamic.” This means if you feel a “flare” in one condition, you should proactively check the others [6]. For example, a thyroid flare can cause significant blood sugar spikes, which increases the risk of Diabetic Ketoacidosis (DKA) if you have Type 1 Diabetes, making close glucose monitoring essential [10].

Management Checklist

  • [ ] Baseline Labs: Ensure you have current levels for TSH, A1c, B12, and Iron [5].
  • [ ] Antibody Check: Confirm your 21-hydroxylase antibodies are negative (to rule out Addison’s disease) [1].
  • [ ] Specialist Sync: Verify that your endocrinologist and gastroenterologist have each other’s contact information.
  • [ ] B12 Strategy: If you have 3B, discuss whether oral or injectable B12 is best for you; most patients can maintain healthy levels with high-dose oral supplements [11].

Return to the Home Page.

Common questions in this guide

Why is levothyroxine an important treatment for APS-3?
Levothyroxine is a synthetic thyroid hormone that normalizes your metabolism. Because your metabolism affects how your body processes other hormones like insulin, stabilizing your thyroid is essential for managing the rest of your APS-3 conditions.
How does treating my thyroid affect my diabetes in APS-3?
When you start thyroid medication and your metabolism normalizes, your body clears insulin faster. This often means you will need to increase your insulin doses to prevent high blood sugar levels.
What specialists should be on my APS-3 care team?
A comprehensive APS-3 care team should be led by an endocrinologist. Depending on your specific subtypes, you may also need a gastroenterologist to monitor your stomach health, a rheumatologist for joint issues, and a primary care physician to coordinate your general health.
Why do I need an endoscopy if I have APS-3B?
If you have APS-3B, you are at a higher risk for autoimmune gastritis, which can cause precancerous changes in the stomach over time. Medical guidelines recommend an endoscopy every three to five years to monitor your stomach health and catch any issues early.
Can a flare-up in one APS-3 condition cause problems with another?
Yes, because your endocrine system is highly interconnected, a flare in one area often impacts the others. For example, a sudden shift in your thyroid function can cause dangerous blood sugar spikes if you also have Type 1 diabetes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do you plan to coordinate with my other specialists (like my gastroenterologist or rheumatologist) to ensure my treatments don't conflict?
  2. 2.If my thyroid levels fluctuate, what specific protocol should I follow to adjust my insulin doses (for 3A) or other medications?
  3. 3.Given that I have APS-3B, will you be referring me for a baseline endoscopy, and what is your recommended frequency for surveillance?
  4. 4.Can we set up a shared portal or communication system where all my specialists can see my recent lab results in real-time?
  5. 5.What specific 'red flag' symptoms should trigger an unscheduled check-up between our regular annual screenings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy.

    Betterle C, Furmaniak J, Sabbadin C, et al.

    Journal of endocrinological investigation 2023; (46(4)):643-665 doi:10.1007/s40618-022-01994-1.

    PMID: 36609775
  2. 2

    Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study.

    Guarnotta V, Pillitteri G, Gambino G, et al.

    Journal of endocrinological investigation 2021; (44(7)):1387-1394 doi:10.1007/s40618-020-01421-3.

    PMID: 33099763
  3. 3

    Increased frequency of microalbuminuria in patients with type 3 autoimmune polyglandular syndrome (APS) compared to isolated autoimmune type 1 diabetes mellitus: A real-life study.

    Radellini S, Vigneri E, Ferreri O, et al.

    Diabetes research and clinical practice 2024; (213()):111746 doi:10.1016/j.diabres.2024.111746.

    PMID: 38885744
  4. 4

    [An adult case of Hashimoto's thyroiditis accompanying pernicious anemia and subacute combined degeneration].

    Shimozono K

    Rinsho shinkeigaku = Clinical neurology 2021; (61(7)):461-465 doi:10.5692/clinicalneurol.cn-001551.

    PMID: 34148933
  5. 5

    Iron and ferritin deficiency in women with hypothyroidism and chronic lymphocytic thyroiditis - systematic review.

    Gierach M, Rudewicz M, Junik R

    Endokrynologia Polska 2024; (75(3)):253-261 doi:10.5603/ep.97860.

    PMID: 38923898
  6. 6

    The "polyglandular crisis" behind recurrent hyponatremia: misdiagnosis of a case of autoimmune polyglandular syndrome type 2 and clinical lessons learned.

    Yan M, Wu H, Deng J, et al.

    Frontiers in immunology 2026; (17()):1744295 doi:10.3389/fimmu.2026.1744295.

    PMID: 41659856
  7. 7

    Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI].

    Lahner E, Zagari RM, Zullo A, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2019; (51(12)):1621-1632 doi:10.1016/j.dld.2019.09.016.

    PMID: 31635944
  8. 8

    [Endocrinology and interdisciplinary consultation in internal medicine : Illustrated using the example of polyglandular autoimmune syndrome].

    Kahaly GJ, Zimmermann J, Hansen MP, et al.

    Der Internist 2017; (58(4)):308-328 doi:10.1007/s00108-017-0201-8.

    PMID: 28233015
  9. 9

    Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.

    Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al.

    Endoscopy 2019; (51(4)):365-388 doi:10.1055/a-0859-1883.

    PMID: 30841008
  10. 10

    Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor.

    Aotani R, Ohkuma T, Oshiro A, et al.

    Case reports in endocrinology 2025; (2025()):8872854 doi:10.1155/crie/8872854.

    PMID: 41322011
  11. 11

    Intramuscular Cyanocobalamin Treatment in Patients with Corpus Atrophic Gastritis and Vitamin B12 Deficiency: Efficacy and Predictors of Increased Requirement-A Monocentric Longitudinal Real-Life Cohort Study.

    Schiavone FP, Pivetta G, Scalamonti S, et al.

    Nutrients 2026; (18(2)) doi:10.3390/nu18020271.

    PMID: 41599884

This page provides management strategies for APS-3 for educational purposes only. Always consult your endocrinologist and multidisciplinary care team before adjusting any medications.

Get notified when new evidence is published on Autoimmune polyendocrinopathy type 3.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.